The Effectiveness of Sirolimus Treatment in Two Rare Disorders with Nonketotic Hypoinsulinemic Hypoglycemia: The Role of mTOR Pathway
Open Access
- 25 November 2020
- journal article
- research article
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 12 (4), 439-443
- https://doi.org/10.4274/jcrpe.galenos.2020.2019.0084
Abstract
Nonketotic-hypoinsulinemic hypoglycemia (NkHH) is a very rare problem charcterized by increase in glucose consumption without hyperinsulinism. This disorder has mainly been reported in cases with AKT2 mutation and rarely in cases with PTEN mutation. In cases with PTEN or AKT2 mutation, there is no effective therapy other than frequent feeding to counter hypoglycemia. The mammalian target of rapamicin (mTOR) inhibitor, sirolimus, has been used in hyperinsulinemic hypoglycemia that was unresponsive to other medical treatment. In the insulin signaling pathway, both AKT2 and PTEN function upstream of mTOR. However, the role of Sirolimus on hypoglycemia in AKT2 and PTEN mutations is unknown. Case 1: Six month-old female with AKT2 mutation [c.49G > A (p.E17K)] and evidence of NkHH. Frequent feeding was unsuccesful in correcting hypoglycemia and her proptosis continued to worsen. Sirolimus treatment was started at three years of age. Subsequently, blood glucose (BG) levels increased to normal levels. Case 2: In a male with PTEN mutation (p.G132V (c.395G>T), persistent NkHH started at 16 years of age (fasting BG: 27 mg/dL, fasting insulin 1.5 mmol/L, while ketone negative). Sirolimus treatment was started and hypoglycemia was succesfully controlled. NkHH is a very rare and serious disorder which is challenging, both for diagnosis and treatment. Additionally, AKT2 and PTEN mutations may result in NkHH. Sirolimus treatment, through mTOR inhibition, appeared to be effectively controlling the peristent hypoglycemia and may be a life-saving therapy in this NkHH due to AKT2 and PTEN mutations.Keywords
This publication has 19 references indexed in Scilit:
- Congenital Hyperinsulinism: Diagnosis and Treatment UpdateJournal of Clinical Research in Pediatric Endocrinology, 2018
- Constitutive Activation of AKT2 in Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic DyslipidemiaJournal of Clinical Endocrinology & Metabolism, 2017
- Sirolimus Therapy in Congenital Hyperinsulinism: A Successful Experience Beyond InfancyPEDIATRICS, 2015
- MORFAN Syndrome: An Infantile Hypoinsulinemic Hypoketotic Hypoglycemia Due to an AKT2 MutationThe Journal of Pediatrics, 2015
- Activating AKT2 Mutation: Hypoinsulinemic Hypoketotic HypoglycemiaJournal of Clinical Endocrinology & Metabolism, 2014
- Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studiesPediatric Research, 2013
- An Activating Mutation of AKT2 and Human HypoglycemiaScience, 2011
- A general introduction to the biochemistry of mitochondrial fatty acid β‐oxidationJournal of Inherited Metabolic Disease, 2010
- A germlinePTEN mutation with manifestations of prenatal onset and verrucous epidermal nevusAmerican Journal of Medical Genetics Part A, 2006
- Hypoketotic Hypofattyacidaemic Hypoinsulinaemic Hypoglycaemia in a Child with Hemihypertrophy? A New SyndromeHormone Research in Paediatrics, 2004